- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
BREAKING NEWS: Meta-Analysis Finds Increased Risk of MI with Rosiglitazone (Avandia)
CLEVELAND -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.
CLEVELAND, May 21 -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
